MammaPrint High1/High2 risk class as a biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL

被引：0

作者：

Wolf, Denise M. ^{[1
]}

Yau, Christina ^{[1
]}

Sanil, Ashish ^{[2
]}

Chien, Jo ^{[1
]}

Wallace, Anne ^{[3
]}

DeMichele, Angela ^{[4
]}

Kaplan, Hank ^{[5
]}

Yee, Doug ^{[6
]}

Isaacs, Claudine ^{[7
]}

Albain, Kathy ^{[8
]}

Viscuzi, Rebecca ^{[9
]}

Boughey, Judy ^{[10
]}

Moulder, Stacey ^{[11
]}

Chui, Steven ^{[12
]}

Khan, Qamar ^{[13
]}

Styblo, Toncred ^{[14
]}

Edmiston, Kirsten ^{[15
]}

Northfelt, Donald ^{[16
]}

Elias, Anthony ^{[17
]}

Haley, Barbara ^{[18
]}

Tripathy, Debu ^{[19
]}

Brown-Swigart, Lamorna ^{[1
]}

Flynn, Susan ^{[1
]}

Hirst, Gillian ^{[1
]}

Buxton, Meredith ^{[1
]}

Hylton, Nola ^{[1
]}

Paoloni, Melissa ^{[20
]}

Symmans, Fraser ^{[11
]}

Esserman, Laura ^{[1
]}

Berry, Don ^{[2
]}

Rugo, Hope ^{[1
]}

Olopade, Olufunmilayo I. ^{[21
]}

van 't Veer, Laura ^{[1
]}

机构：

[1] Univ Calif, Davis, CA USA

[2] Berry Consultants LLC, Austin, TX USA

[3] Univ Calif San Diego, San Diego, CA 92103 USA

[4] Univ Penn, Philadelphia, PA 19104 USA

[5] Swedish Canc Inst, Seattle, WA USA

[6] Univ Minnesota, Minneapolis, MN 55455 USA

[7] Georgetown Univ, Washington, DC 20057 USA

[8] Loyola Univ Med Ctr, Maywood, IL 60153 USA

[9] Univ Arizona, Tucson, AZ 85721 USA

[10] Mayo Clin, Rochester, MN USA

[11] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[12] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[13] Univ Kansas, Med Ctr, Lawrence, KS 66045 USA

[14] Emory Univ, Atlanta, GA 30322 USA

[15] Inova Hlth Syst, Washington, DC USA

[16] Mayo Clin, Rochester, MI USA

[17] Univ Colorado, Colorado Springs, CO USA

[18] Univ Texas, Houston, TX USA

[19] Univ So Calif, Los Angeles, CA 90089 USA

[20] QuantumLeap Healthcare, Los Angeles, CA USA

[21] Univ Chicago, Chicago, IL 60637 USA

来源：

CANCER RESEARCH | 2015年 / 75卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3-06-25

引用

页数：2

共 50 条

[41] Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial
Denise M. Wolf
Christina Yau
Julia Wulfkuhle
Lamorna Brown-Swigart
Rosa I. Gallagher
Mark Jesus M. Magbanua
Nick O’Grady
Gillian Hirst
Smita Asare
Debu Tripathy
Don Berry
Laura Esserman
A. Jo Chien
Emanuel F. Petricoin
Laura van ‘t Veer
npj Breast Cancer, 6
[42] Characterizing the biology and response of locally advanced breast cancer in women undergoing neoadjuvant therapy: preliminary results from the I-SPY trial
Hylton, N.
Carey, L.
DeMichele, A.
Blume, J.
Broadwater, G.
Madhavan, S.
Rosen, M.
George, S.
Esserman, L.
BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S22 - S22
[43] Challenges of achieving high image quality on breast MRI for quantitative measurements in the I-SPY 2 TRIAL
Bareng, Teffany Joy
Gibbs, Jessica E.
Onishi, Natsuko
Newitt, David C.
LeStage, Barbara
Hylton, Nola M.
CANCER RESEARCH, 2022, 82 (04)
[44] Evaluation of ANG/TIE/hypoxia pathway genes and signatures as predictors of response to trebananib (AMG 386) in the neoadjuvant I-SPY 2 TRIAL for Stage II-III high-risk breast cancer
Wolf, Denise M.
Yau, Christina
Brown-Swigart, Lamorna
Hirst, Gillian
Asare, Smita
Schwab, Richard
Berry, Don
Esserman, Laura
Albain, Kathy S.
Leland-Jones, Brian
van 't Veer, Laura
CANCER RESEARCH, 2018, 78 (13)
[45] Analysis of DNA repair deficiency biomarkers as predictors of response to the PD1 inhibitor pembrolizumab: Results from the neoadjuvant I-SPY 2 trial for stage II-III high-risk breast cancer
Yau, Christina
Wolf, Denise
Brown-Swigart, Lamorna
Hirst, Gillian
Sanil, Ashish
Singhrao, Ruby
Asare, Smita
DeMichele, Angela
Berry, Don
Esserman, Laura
van 't Veer, Laura
Nanda, Rita
Liu, Minetta
Yee, Douglas
CANCER RESEARCH, 2018, 78 (04)
[46] Operational standardization and quality assurance yield high acceptance rate for breast MRI in the I-SPY 2 TRIAL
Gibbs, Jessica
Newitt, David C.
Watkins, Margarita
Li, Wen
Cimino, Lisa
Li, Clifton
Onishi, Natsuko
Wilmes, Lisa J.
Bareng, Teffany Joy
Proctor, Evelyn
LeStage, Barbara
Parker, Bev
Hylton, Nola M.
CANCER RESEARCH, 2021, 81 (04)
[47] Evaluation of talazoparib in combination with irinotecan in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL
Schwab, Richard
Clark, Amy S.
Yau, Christina
Hylton, Nola
Li, Wen
Wolfe, Denise
Chien, A. Jo
Wallace, Anne M.
Forero-Torres, Andres
Stringer-Reasor, Erica
Nanda, Rita
Jaskowiak, Nora
Boughey, Judy
Haddad, Tufia
Han, Heather S.
Lee, Catherine
Albain, Kathy
Isaacs, Claudine
Elias, Anthony D.
Ellis, Erin D.
Shah, Payal
Lang, Julie E.
Lu, Janice
Tripathy, Debasish
Kemmer, Kathleen
Yee, Douglas
Haley, Barbara
Majure, Melanie
Roesch, Erin
Vaklavas, Christos
Ewing, Cheryl
Helsten, Teresa
Symmans, W. Fraser
Perlmutter, Jane
Rugo, Hope S.
Melisko, Michelle
Wilson, Amy
Singhrao, Ruby
van't Veer, Laura
De Michele, Angela
Asare, Smita
Berry, Don
Esserman, Laura J.
CANCER RESEARCH, 2019, 79 (13)
[48] DNA repair deficiency biomarkers and identification of ER-positive breast cancer patients who may benefit from veliparib/carboplatin: Results from the I-SPY 2 trial.
van't Veer, Laura
Esserman, Laura
Sanil, Ashish
Glas, Annuska
Severson, Tessa
Linn, Sabine C.
Swigart, Lamorna Brown
Hirst, Gillian
Olopade, Olufunmilayo I.
Rugo, Hope S.
Berry, Don
Wolf, Denise M.
Yau, Christina
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[49] Evaluation of Tucatinib plus (Paclitaxel plus Pertuzumab plus Trastuzumab) followed by AC in high-risk HER2 positive (HER2+) stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Potter, David A.
Roesch, Erin
Yau, Christina
Lu, Ruixiao
Wolf, Denise
Samson, Susan
Stafford, Debra
Albain, Kathy S.
Isaacs, Claudine
Trivedi, Meghana
Yee, Douglas
Boughey, Judy
Thomas, Alexandra
Chien, A. Jo
Hylton, Nola
Li, Wen
DeMichele, Angela
Perlmutter, Jane
Symmans, W. Fraser
Hershman, Dawn L.
Melisko, Michelle
Veer, Laura J. van ' t
Wilson, Amy
Asare, Smita M.
Berry, Donald A.
Schwab, Richard
Rugo, Hope S.
Esserman, Laura J.
CANCER RESEARCH, 2022, 82 (04)
[50] Efficacy of T-DM1+pertuzumab over standard therapy for HER2+breast cancer: Results from the neoadjuvant I -SPY 2 TRIAL
DeMichele, Angela M.
Moulder, Stacy
Buxton, Meredith
Yee, Douglas
Wallace, Anne
Chien, Jo
Isaacs, Claudine
Albain, Kathy
Boughey, Judy
Kemmer, Kathleen
Haley, Barbara
Lang, Julie
Kaplan, Henry
Minton, Susan
Forero, Andres
Elias, Anthony
Nanda, Rita
Korde, Larissa
Schwab, Richard
Melisko, Michelle
Sanil, Ashish
Hogarth, Michael
Hylton, Nola
Paoloni, Melissa
Symmans, Fraser
Perlmutter, Jane
Lyandres, Julia
Yau, Christina
Berry, Don
Esserman, Laura
CANCER RESEARCH, 2016, 76

← 1 2 3 4 5 →